BACKGROUND: A preliminary report in six patients suggested that deep brain stimulation (DBS) of the subcallosal cingulate gyrus (SCG) may provide benefit in treatment-resistant depression (TRD). We now report the results of these and an additional 14 patients with extended follow-up. METHODS: Twenty patients with TRD underwent serial assessments before and after SCG DBS. We determined the percentage of patients who achieved a response (50% or greater reduction in the 17-item Hamilton Rating Scale for Depression [HRSD-17]) or remission (scores of 7 or less) after surgery. We also examined changes in brain metabolism associated with DBS, using positron emission tomography. RESULTS: There were both early and progressive benefits to DBS. One month after surgery, 35% of patients met criteria for response with 10% of patients in remission. Six months after surgery, 60% of patients were responders and 35% met criteria for remission, benefits that were largely maintained at 12 months. Deep brain stimulation therapy was associated with specific changes in the metabolic activity localized to cortical and limbic circuits implicated in the pathogenesis of depression. The number of serious adverse effects was small with no patient experiencing permanent deficits. CONCLUSIONS: This study suggests that DBS is relatively safe and provides significant improvement in patients with TRD. Subcallosal cingulate gyrus DBS likely acts by modulating brain networks whose dysfunction leads to depression. The procedure is well tolerated and benefits are sustained for at least 1 year. A careful double-blind appraisal is required before the procedure can be recommended for use on a wider scale.
BACKGROUND: A preliminary report in six patients suggested that deep brain stimulation (DBS) of the subcallosal cingulate gyrus (SCG) may provide benefit in treatment-resistant depression (TRD). We now report the results of these and an additional 14 patients with extended follow-up. METHODS: Twenty patients with TRD underwent serial assessments before and after SCG DBS. We determined the percentage of patients who achieved a response (50% or greater reduction in the 17-item Hamilton Rating Scale for Depression [HRSD-17]) or remission (scores of 7 or less) after surgery. We also examined changes in brain metabolism associated with DBS, using positron emission tomography. RESULTS: There were both early and progressive benefits to DBS. One month after surgery, 35% of patients met criteria for response with 10% of patients in remission. Six months after surgery, 60% of patients were responders and 35% met criteria for remission, benefits that were largely maintained at 12 months. Deep brain stimulation therapy was associated with specific changes in the metabolic activity localized to cortical and limbic circuits implicated in the pathogenesis of depression. The number of serious adverse effects was small with no patient experiencing permanent deficits. CONCLUSIONS: This study suggests that DBS is relatively safe and provides significant improvement in patients with TRD. Subcallosal cingulate gyrus DBS likely acts by modulating brain networks whose dysfunction leads to depression. The procedure is well tolerated and benefits are sustained for at least 1 year. A careful double-blind appraisal is required before the procedure can be recommended for use on a wider scale.
Authors: Marie J C Forgeard; Emily A P Haigh; Aaron T Beck; Richard J Davidson; Fritz A Henn; Steven F Maier; Helen S Mayberg; Martin E P Seligman Journal: Clin Psychol (New York) Date: 2011-12
Authors: James M Broadway; Paul E Holtzheimer; Matthew R Hilimire; Nathan A Parks; Jordan E Devylder; Helen S Mayberg; Paul M Corballis Journal: Neuropsychopharmacology Date: 2012-03-14 Impact factor: 7.853
Authors: Jonathan A Hyam; Morten L Kringelbach; Peter A Silburn; Tipu Z Aziz; Alexander L Green Journal: Nat Rev Neurol Date: 2012-06-12 Impact factor: 42.937
Authors: Maher A Quraan; Andrea B Protzner; Zafiris J Daskalakis; Peter Giacobbe; Chris W Tang; Sidney H Kennedy; Andres M Lozano; Mary P McAndrews Journal: Neuropsychopharmacology Date: 2013-11-28 Impact factor: 7.853